These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9750522)

  • 1. [Antiandrogen withdrawal syndrome].
    Akimoto S
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
    Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA; Strup SE; Gomella LG
    Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
    Paul R; Breul J
    Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.
    Noguchi K; Teranishi J; Uemura H; Fujikawa N; Saito K; Murai T
    Int J Urol; 2006 Sep; 13(9):1259-61. PubMed ID: 16984567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
    Akakura K; Akimoto S; Furuya Y; Ito H
    Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the antiandrogen withdrawal syndrome.
    Miyamoto H; Rahman MM; Chang C
    J Cell Biochem; 2004 Jan; 91(1):3-12. PubMed ID: 14689576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiandrogen withdrawal syndrome.
    Wirth MP; Froschermaier SE
    Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
    Akakura K; Akimoto S; Ohki T; Shimazaki J
    Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

  • 16. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
    Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ;
    J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
    Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
    Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
    South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.